Growing partnerships Target major orthopedic centers and hospitals that regularly use exsanguinating tourniquets to expand distribution through group purchasing organizations and national supplier contracts, leveraging HemaClear's established case studies from leading institutions.

Expansion opportunities Leverage the proven adoption in large hospitals to upsell to adjacent surgical specialties and perioperative teams in the same facilities, highlighting speed of application, sterile single-use design, and reduced need for reprocessing.

Cost efficiency Position HemaClear as a cost-saving solution for ORs by emphasizing device simplicity, minimal setup time, and elimination of bulky equipment, appealing to procurement analysts focused on total room efficiency and patient throughput.

Clinical differentiation Highlight the device’s 95% exsanguination capability and wide surgical field to surgeons seeking improved visibility and control, pairing with clinical champions to drive clinician-led adoption in new markets.

Strategic funding cues Identify potential partnerships with large medical device players or distributors that serve the same customer base as Getinge, Edwards Lifesciences, and Terumo Cardiovascular to accelerate market access and co-marketing opportunities.